Introduction
============

It has been shown that the levels of different adipokines, such as leptin, adiponectin, resistin, vaspin, omentin-1 and RBP4 are higher in women than those in men ([@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6]), and that estrogens stimulate secretion of some adipokines, while androgens exert an opposite effect ([@bib1], [@bib2], [@bib6]). Additionally, it has been shown that some adipokines modulate reproductive functions, both indirectly by affecting the pituitary--ovary axis and directly by acting on ovarian receptors. The stimulation of leptin receptors in hypothalamus is necessary to activate the hypothalamus--pituitary--gonadal (HPG) axis to trigger puberty and maintain reproductive function ([@bib7]). Also, the activation of leptin and adiponectin receptors in the pituitary gland have promoting effect on gonadotropin secretion, while the stimulation of apelin receptors have an opposite effect ([@bib6], [@bib8]). Furthermore, higher leptin levels have deleterious effect on ovarian steroidogenesis ([@bib7]). These data suggest the existence of both positive and negative feedback between adipokines, gonadotrophins and ovarian hormones.

The results of previously published studies which assessed changes of selected adipokine levels during the physiological menstrual cycle were contradictory. For example, the higher circulating leptin level was found during the luteal phase by some researchers ([@bib9], [@bib10], [@bib11], [@bib12]); however, Cappobianco and coworkers ([@bib12]) did not observe any changes in leptin levels during the menstrual cycle in both ovulatory and anovulatory women. Additionally, in some ([@bib13]), but not in other studies ([@bib14]), the association between changes in plasma leptin levels and variations of both estradiol and progesterone release were observed during the menstrual cycle. Similarly, the results of studies which assessed changes in resistin and adiponectin levels during the physiological menstrual cycle are ambiguous. Asimakopoulos and coworkers ([@bib10]) observed that plasma adiponectin concentration remains stable during the menstrual cycle, while circulating resistin levels were higher in the luteal than in the follicular and the midcycle phase. However, Dafopoulos and coworkers ([@bib15]) did not find any significant changes in circulating resistin levels during the physiological menstrual cycle. Furthermore, Galván and coworkers ([@bib16]) have shown lower plasma adiponectin levels in the luteal than in the follicular and the midcycle phase. Moreover, the results of some studies revealed the lack of relationships between adiponectin or resistin levels and estradiol or progesterone concentrations in the circulation ([@bib16], [@bib17], [@bib18], [@bib19]). It seems that the inconsistencies in the previously cited data are the result of having small size of study cohorts, and in some cases, the inclusion of overweight women. The lack of TNF-alpha changes during the menstrual cycle has been observed in a single study ([@bib20]), while plasma concentrations of omentin, visfatin/NAMPT, vaspin, apelin-36, RBP4 and IL-6 have not yet been studied during the physiological menstrual cycle. Finally, there were limited data available on the association between serum levels of ovarian steroids or gonadotrophins and plasma visfatin/NAMPT, vaspin, omentin-1, apelin-36, RBP4 and IL-6 in normal-weight women. Due to the existing inconsistencies in previously published studies, our study focused on the assessment of plasma leptin, adiponectin, resistin, visfatin/NAMPT, omentin-1, vaspin, apelin, TNF-α, IL-6 and RBP4 levels in relation to hormonal changes during the menstrual cycle in young, healthy, normal-weight women.

Material and methods
====================

The study involved 52 healthy, normal-weight women, aged 18--30 years, with regular menstrual cycles and a stable body mass index (BMI) during the 3-month period before the study. Patients diagnosed with polycystic ovary syndrome (PCOS), Cushing's syndrome, thyroid dysfunctions, androgen-secreting tumor, and enzyme deficiency (21-hydroxylase in particular), decreased ovary reserves, type 1 and 2 diabetes were excluded in our study. Any cases with pharmacological therapy, smoking or alcohol abuse were also excluded.

The study was conducted among patients referred from contraceptive consulting after obtaining the informed consent from each participant. The study protocol was approved by the Bioethical Committee of Medical University of Silesia in Katowice. Normal weight was defined according to WHO criteria ([@bib21]) as BMI between 18.5 and 24.9 kg/m^2^. The data concerning general and gynecological health were obtained on the basis of medical history as well as general and gynecological examinations. The characteristics of the study group are presented in [Table 1](#tbl1){ref-type="table"}. Table 1Patients characteristics.***N* = 52**Age (years)21.5 ± 1.5Body mass (kg)58.5 ± 5.4BMI (kg/m^2^)21.3 ± 1.6Body fat (kg)15.9 ± 2.9Body fat (%)27.1 ± 3.2Waist circumference (cm)70.8 ± 3.7Menarche (year of age)12.7 ± 0.9Menstrual cycle duration (days)28.6 ± 2.1

Anthropometric measurements (body mass, height and waist circumference) were performed and BMI was calculated according to the standard formula. Body composition was assessed by the bioimpedance method, using Bodystat 1500 (Douglas, Isle of Man). After 16 h of fasting overnight, 15 mL samples of venous blood were withdrawn in the morning between 8:00 and 9:00 h. The blood samples were collected between days 2 and 4 of the follicular phase, between days 12 and 14 of the midcycle phase and between days 24 and 26 of the luteal phase of each subject's menstrual cycle. These blood samples were collected according to recommendations of the kit's manufacturers. The serum and plasma samples were frozen and stored at −70°C.

Laboratory procedures
---------------------

Serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), estradiol (E~2~), total testosterone, free testosterone, androstendione, DHEA-S and SHBG were determined by ELISA (DRG Instruments GmbH, Marburg, Germany). The respective intra- and inter-assay coefficients of variations were 5.5% and 6.1% for FSH, 5.6% and 6.2% for LH, 4.5% and 5.9% for PRL, 4.7% and 7.8% for E2, 3.6% and 7.1% for testosterone, 6.4% and 8.0% for free testosterone, 6.5% and 10.2% for androstendione, 4.8% and 7.5% for DHEA-S and 5.3% and 9.0% for SHBG. Also, plasma glucose was estimated by colorimetric method using a commercially available test kit (Roche). Moreover, serum insulin and progesterone levels were assessed by the electrochemilumine­scence method on the Cobas E411 analyzer (Roche Diagnostics GmbH), with inter-assay coefficients of variability below 3.8% and below 11.8%, respectively. In addition, HOMA-IR was calculated according to the standard formula: HOMA-IR = fasting serum insulin (μIU/mL) × fasting glucose (mg/dL)/405. The cutoff value for insulin resistance was ≥2.5.

The ELISA method was also used for measurements of plasma leptin (TECOmedical AG, Sissach, Switzerland), adiponectin (TECOmedical AG), resistin (R&D Systems), visfatin/NAMPT (BioVendor, Brno, Czech Republic), omentin-1 (BioVendor), vaspin (BioVendor), apelin-36 (Phoenix Pharmaceuticals, Burlingame, CA, USA), TNF-alpha (R&D Systems), IL-6 (R&D Systems) and RBP4 (Phoenix Pharmaceuticals), with the lower limit of sensitivity of 0.2, 0.6, 0.05, 0.03, 0.5, 0.01, 0.11, 0.18, 0.02 and 2.17 ng/mL, respectively. The intra- and inter-assay coefficients of variations were 7% and 8% for leptin, 5% and 6% for adiponectin, 5% and 5% for resistin, 9% and 6% for visfatin/NAMPT, 4% and 5% for omentin-1 and 9% and 10% for vaspin, 5.0--10.0% and \<15.0% for apelin-36, 14.4% and 18.7% for TNF-alpha, 7.4% and 7.8% for IL-6 and 5.0% and \<14.0% for RBP4.

Statistical analysis
--------------------

The statistical analyses were performed using STATISTICA 10.0 PL (StatSoft, Krakow, Poland) software and R software environment. The results are presented as mean values ± [s.d.]{.smallcaps}, and the distribution of variables was evaluated by the D'Agostino--Pearson test. The homogeneity of variances was assessed by the Levene test. Of note, the quantitative variables were compared with multivariate analysis of variances for repeated measurements with Tukey's *post hoc* test. In case of violence of the sphericity test, multivariate tests were applied. The assessment of associations between variables was performed with multivariate linear regression and the outliers were identified based on Cook's distance values. The Cook--Weisberg test was used to test the residuals for heteroskedasticity, and *η* ^2^ was used as the effect size estimate for the regression analysis. All the results were considered as statistically significant with a *P* value of \<0.05.

Results
=======

As was expected, the serum FSH level was significantly higher in the midcycle than that in the follicular and the luteal phases, and it was higher in the follicular phase than that in the luteal phase of the menstrual cycle. Moreover, serum LH and estradiol levels were significantly increased in the midcycle than those in both the follicular and the luteal phases, and they were determined to be higher in the luteal than in the follicular phase. Serum progesterone and total testosterone levels were significantly lower in the follicular phase than in both the midcycle and the luteal phases of the menstrual cycle. Additionally, serum SHBG levels were significantly lower in the midcycle than in both the follicular and the luteal phases of the menstrual cycle ([Table 2](#tbl2){ref-type="table"}). However, there was no difference in insulin levels during the menstrual cycle phases ([Table 2](#tbl2){ref-type="table"}). Plasma adiponectin, omentin-1, resistin, visfatin/NAMPT, apelin-36, TNF-α, IL-6 and RBP4 concentrations were stable, while leptin and vaspin levels significantly increased in both the midcycle and the luteal phases compared to the follicular phase of the menstrual cycle (*P* \< 0.01 and *P* \< 0.01, respectively; [Table 2](#tbl2){ref-type="table"}). Table 2The hormones and adipokines changes during the menstrual cycle.**Follicular phaseMidcycleLuteal phase*P*∆~1~ M-FP∆~2~ LP-FP**FSH (IU/mL)5.9 ± 2.06.7 ± 3.23.8 ± 1.9\<0.0010.7 ± 3.22.8 ± 3.0LH (IU/mL)7.0 ± 2.817.4 ± 11.710.1 ± 4.1\<0.00110.3 ± 11.0−0.2 ± 9.6PRL (ng/mL)14.0 ± 8.713.0 ± 6.814.7 ± 6.40.27−0.2 ± 9.6−1.5 ± 7.0Estradiol (pg/mL)29.8 ± 19.1113.7 ± 75.656.2 ± 27.0\<0.00180.5 ± 72.455.6 ± 72.2Progesterone (ng/mL)0.23 ± 0.160.45 ± 0.486.15 ± 6.40\<0.0010.21 ± 0.485.71 ± 6.3517-OH progesterone (ng/mL)0.7 ± 0.41.1 ± 0.62.2 ± 1.6\<0.0010.3 ± 0.4−1.2 ± 1.5Androstendione (ng/mL)2.6 ± 1.42.4 ± 1.12.4 ± 1.10.30−0.2 ± 1.0−0.01 ± 1.0DHEA-S (μg/mL)2.8 ± 1.02.9 ± 1.32.8 ± 1.20.070.2 ± 0.60.1 ± 0.6Total testosterone (ng/mL)0.8 ± 0.81.0 ± 1.31.0 ± 1.4\<0.050.2 ± 1.10.1 ± 0.6SHBG (nmol/L)65.6 ± 38.559.8 ± 37.166.8 ± 43.90.15−5.8 ± 28.3−7 ± 29.3Glucose (mg/dL)82.8 ± 10.182.9 ± 11.583.1 ± 13.60.980.13 ± 11.8−0.25 ± 15.7Insulin (µIU/mL)8.8 ± 5.48.6 ± 3.88.7 ± 4.20.96−0.2 ± 5.3−0.1 ± 5.1HOMA-IR1.7 ± 0.91.8 ± 0.91.8 ± 1.00.810.1 ± 1.1−0.1 ± 1.1Adiponectin (μg/mL)21.0 ± 9.723.0 ± 14.123.6 ± 14.20.152.0 ± 10.7−0.5 ± 4.7Leptin (ng/mL)16.3 ± 13.119.9 ± 17.519.8 ± 14.2\<0.013.6 ± 9.00.2 ± 11.3Omentin-1 (ng/mL)534 ± 245532 ± 226533 ± 2160.9914.5 ± 199−1.1 ± 249Resistin (ng/mL)10.0 ± 3.010.0 ± 3.59.4 ± 3.00.18−0.1 ± 2.80.6 ± 3.5Visfatin (pg/mL)0.8 ± 0.81.0 ± 0.90.7 ± 0.70.060.1 ± 1.20.2 ± 1.1Vaspin (ng/mL)0.25 ± 0.150.31 ± 0.240.33 ± 0.27\<0.010.1 ± 0.2−0.02 ± 0.2Apelin-36 (ng/mL)1.7 ± 1.01.8 ± 1.31.6 ± 1.20.250.1 ± 1.10.2 ± 1.0IL-6 (pg/mL)1.2 ± 0.61.1 ± 1.01.0 ± 0.50.42−0.01 ± 1.10.1 ± 1.1TNF-α (pg/mL)1.2 ± 0.71.1 ± 0.61.1 ± 0.60.22−0.1 ± 0.50.03 ± 0.4RBP-4 (ng/mL)42.4 ± 24.238.0 ± 17.739.7 ± 19.00.37−4.3 ± 26.0−1.6 ± 18.2

Correlations between studied hormones or adipokines and anthropometric parameters
---------------------------------------------------------------------------------

There were significant inverse correlations between serum SHBG levels and waist circumference in the follicular, midcycle and luteal phases of the menstrual cycle. Additionally, regardless of the menstrual cycle phase, positive correlations were found between plasma leptin levels and body fat mass or percentage, while negative correlations were found between plasma adiponectin levels and waist circumference. There were no correlations between the anthropometric parameters and either the remaining studied hormones or the remaining studied adipokines ([Table 3](#tbl3){ref-type="table"}). Table 3Correlations between studied hormones and adipokines and anthropometrics parameters.**Follicular phaseMidcycleLuteal phase**SHBGleptinadiponectinSHBGleptinadiponectinSHBGLeptinadiponectinWaist circumferenceR = −0.33; *P* = 0.02R = −0.37; *P* \< 0.01R = −0.38; *P* = 0.01R = −0.46; *P* \< 0.001R = −0.36; *P* = 0.01R = −0.30; *P* = 0.03Fat mass (kg)--R = 0.48; *P* \< 0,001----R = 0.35; *P* = 0,02----R = 0.39; *P* \< 0,01--Fat mass (%)--R = 0.41; *P* \< 0.01----R = 0.33; *P* = 0.02----R = 0.37; *P* \< 0.01--

Correlations between studied hormones and the levels of adipokines
------------------------------------------------------------------

No correlations were present between serum gonadotrophin levels and the levels of the studied adipokines in the follicular and the luteal phases of the menstrual cycle, while positive correlations were found between serum LH levels and both plasma leptin and resistin concentrations in the midcycle ([Table 4](#tbl4){ref-type="table"}). There were positive correlations between serum PRL levels and both plasma resistin and adiponectin concentrations in the follicular phase; however, these correlations were not observed in the luteal phase. Additionally, serum PRL levels correlated positively with plasma resistin concentrations in the midcycle ([Table 4](#tbl4){ref-type="table"}). Of note, no correlations were observed between the studied adipokines and either serum estradiol or progesterone levels in the follicular phase of the menstrual cycle, while plasma apelin-36 levels were proportional to 17-OH progesterone levels. In addition, in the midcycle, serum 17-OH progesterone concentrations were proportional to both plasma omentin-1 and apelin-36 levels. Furthermore, in the luteal phase of the menstrual cycle, inverse correlations were found between serum estradiol concentrations and plasma visfatin/NAMPT, adiponectin and apelin-36 levels. However, a positive correlation was seen between serum 17-OH progesterone concentrations and plasma adiponectin levels ([Table 4](#tbl4){ref-type="table"}). In both the midcycle and the luteal phases of the menstrual cycle, positive correlations were found between serum androstendione levels and plasma visfatin/NAMPT concentrations. In the midcycle, only plasma omentin-1 concentrations correlated positively with serum androstendione and DHEA-S levels, while in the luteal phase, only plasma visfatin/NAMPT levels were proportional to serum DHEA-S concentrations. In contrast, in the luteal phase, plasma resistin levels correlated inversely with the total testosterone concentrations in the serum ([Table 4](#tbl4){ref-type="table"}). There were positive correlations between serum SHBG and plasma adiponectin levels in both the midcycle and the luteal phases. Moreover, in the luteal phase, only a positive correlation was found between serum SHBG concentrations and plasma vaspin levels ([Table 4](#tbl4){ref-type="table"}). There was a correlation between HOMA-IR values and resistin levels in the follicular phase (R = 0.35), between HOMA-IR values and omentin-1 (R = 0.28), and visfatin/NAMPT (R = −0.28) and RBP4 levels (R = 0.33) in the midcycle, as well as a correlation between HOMA-IR values and leptin levels (R = 0.41) in the luteal phase. Table 4Correlation between studied hormones and adipokines levels.**Follicular phaseMidcycleLuteal phase**ResistinAdiponectinApelin-36LeptinResistinAdiponectinApelin-36Omentin-1Visfatin/NAMPTResistinAdiponectinVisfatin/NAMPTApelin-36VaspinLH------R = 0.38R = 0.37------------------*P* \< 0.05*P* \< 0.05PRLR = 0.34R = 0.30----R = 0.44------------------*P* \< 0.05*P* \< 0.05*P* \< 0.01Estradiol--------R = 0.26----------R = −0.30R = −0.29R = −0.26--*P* = 0.06*P* \< 0.05*P* \< 0.05*P* \< 0.05Progesterone----------------------------17-OH progesterone----R = 0.32------R = 0.29R = 0.35----R = 0.27------*P* \< 0.05*P* \< 0.05*P* \< 0.05*P* \< 0.05Androstendione--------------R = 0.33R = 0.28----R = 0.49----*P* \< 0.05*P* \< 0.05*P* \< 0.001DHEAS--------------R = 0.45------R = 0.35----*P* \< 0.001*P* \< 0.05Total testosterone------------------R = −0.28--------*P* \< 0.05SHBG----------R = 0.47--------R = 0.43--R = 0.32--*P* \< 0.001*P* \< 0.01*P* \< 0.05

Multivariable regression for changes of leptin and vaspin
---------------------------------------------------------

For further analysis of data, two additional classes of variables were created to represent changes in variables between the midcycle and the follicular phase (∆~1~) and the changes between the luteal phase and the follicular phase (∆~2~). A stepwise backward multivariable linear regression was performed to assess the relationships between changes of plasma leptin or vaspin levels and serum FSH, LH, estradiol, progesterone, 17-OH progesterone, total testosterone and insulin levels.

The results of our analysis concerning ∆~1~ changes indicated no statistically significant correlation between changes of leptin and vaspin and the hormones mentioned above, while for ∆~2~ changes, significant correlations were found between changes of leptin and vaspin and changes in total testosterone, 17-OH progesterone and insulin levels ([Table 5](#tbl5){ref-type="table"}). Based on the *η* ^2^ values, the most notable relationship was between the changes in plasma leptin and vaspin levels and the changes in total testosterone levels between the luteal and follicular phases. Table 5Results of multivariable stepwise backward linear regression in assessment between differences in changes of leptin or vaspin and FSH, LH, estradiol, progesterone, 17-OH progesterone, total testosterone and insulin levels.**∆2LeptinVaspin**Variablesβ ± 95% CI*tPη*^2^β ± 95% CI*tPη*^2^Total testosterone (ng/mL)6.22 (1.72--10.72)2.77\<0.0129.10.136 (0.061--0.213)3.60\<0.0141.517-OH progesterone (ng/mL)1.88 (0.12--3.64)2.14\<0.0526.30.031 (0.001--0.0612.08\<0.0513.9Insulin (µIU/mL)0.64 (0.15--1.13)2.63\<0.0517.40.009 (0.001--0.175)2.25\<0.0516.2Constants2.11 (−1.14--5.36)1.300.20--0.009 (−0.046--0.064)0.320.75--

Discussion
==========

To the best of our knowledge, our study is the first attempt to assess the changes of omentin-1, vaspin, visfatin/NAMPT, apelin-36, RBP4 and IL-6 during the physiological menstrual cycle in young, healthy, normal-weight women. The results of our study revealed that plasma adiponectin, resistin, omentin-1, visfatin/NAMPT, apelin-36, RBP4, IL-6 and TNF-α levels were stable during the menstrual cycle, while plasma vaspin levels were increased in both the midcycle and the luteal phases compared to the follicular phase; these increases were proportional to the changes in estrogen and 17-OH progesterone levels. Although we did not observe any associations between plasma vaspin level and either gonadotrophins or sex steroid hormones, the results of multivariate analysis revealed that changes of vaspin levels between the follicular and the luteal phase were associated with changes in total testosterone and 17-OH progesterone levels as well as HOMA-IR values. This hypothesis is supported by the results of previously published studies, which revealed a reduction in adipocyte insulin receptor binding ([@bib22]) and a decrease in insulin sensitivity in the luteal phase in comparison to the follicular phase of the menstrual cycle ([@bib23]). Additionally, the hypothetical insulin-sensitizing effect of vaspin would be in line with positive correlation between levels of vaspin and SHBG in the luteal phase, observed in this study.

Additionally, in accordance with the most previously published studies ([@bib9], [@bib10], [@bib11]), we observed increased leptin levels in both the midcycle and the luteal phases. It should be emphasized that midcycle serum LH concentrations were proportional to the circulating leptin levels, corroborating the role of leptin in the regulation of reproductive function ([@bib7]). Moreover, plasma leptin levels were not associated with either estradiol or progesterone concentrations, which is in line with the results of some ([@bib13]), but not other studies ([@bib14]). However, the results of multivariate analysis revealed that changes in leptin levels between follicular and luteal phase are associated with the changes of total testosterone and 17-OH progesterone levels as well as HOMA-IR values. These results suggest that vaspin and leptin may play a role not only in hormonal changes during the menstrual cycle but also indirectly in the regulation of sexual activity in women. This hypothesis is partially supported by a study performed by Caruso and coworkers ([@bib24]), which showed a linear correlation between sexual activity and the androgenic hormonal profile during the menstrual cycle in women with and without a partner. In addition, the results of multiple regression analysis performed in our study have shown a strong relationship between changes in leptin and vaspin levels and changes in testosterone levels during the menstrual cycle. Further studies are necessary to explain this potential association. Our results, in line with those of previously published studies ([@bib10], [@bib15], [@bib17], [@bib19]), but contrary to others ([@bib16]), revealed stable circulating adiponectin levels during the physiological menstrual cycle. Additionally, contrary to previously published results ([@bib16], [@bib17], [@bib18], [@bib19]), we observed that in the luteal phase, plasma adiponectin levels were inversely associated with circulating estradiol levels and proportional to 17-OH progesterone concentrations. Thus, it seems that stable adiponectin levels during the physiological menstrual cycle are the effect of opposing actions of ovarian sex hormones. Furthermore, inverse associations between circulating adiponectin levels and waist circumference were shown, regardless of the menstrual cycle phase, which is consistent with the previous results ([@bib25]). This observation suggests that visceral fat depot is a stronger factor affecting the amount of adiponectin in the circulation than ovarian hormones. The positive association between adiponectin and SHBG levels also indicates that this adipokine may play an indirect role in the regulation of bioavailability of estrogens and androgens in the midcycle and in the luteal phase. It should be noted that our study shows inverse correlations between serum SHBG and plasma adiponectin levels in all phases of the menstrual cycle. In addition, irrespective of the menstrual cycle phase, plasma leptin levels were proportional to body fat mass and fat percentage, while there were no associations between the remaining studied adipokines and anthropometric parameters. These results suggest that the visceral fat deposit is an important factor affecting adiponectin and SHBG levels in normal-weight women. Furthermore, it seems that changes of SHBG levels are directly associated with changes of adiponectin levels related to visceral fat deposit, while in general, fat deposit is more strongly associated with circulating leptin levels. It should be noted that BMI is a widely recognized parameter in the assessment of nutritional status; however, our data shows that using BMI as the only measure of fat stores can produce conflicting results. It is well known that visceral fat deposits are the place of steroid hormones' metabolism and the main source of adipokines and hormones ([@bib26], [@bib27]). It should also be mentioned that adipose tissue expresses androgen, estrogen and progesterone receptors ([@bib27]). On the other hand, probably due to low physical activity, there are increasing numbers of young women with normal BMI values who develop increased total and visceral fat deposits, known as metabolically obese normal weight (MONW) ([@bib28]). Increased visceral fat deposit is a reason for excessive aromatase activity, inflammation, disturbances in the production and secretion of adipokines, as well as the development of insulin resistance ([@bib29], [@bib30]). Thus, all studies assessing the physiological aspect of the association between hormones of adipose tissue (adipokines) and sex hormones should include more accurate measures of nutritional status than BMI.

Additionally, our results, in accordance with a previous study ([@bib10]) but contrary to another ([@bib15]) revealed stable resistin levels during the menstrual cycle. Of interest, plasma resistin levels were associated with circulating LH and PRL levels in the midcycle. In addition, plasma resistin levels were proportional to the circulating PRL and inversely proportional to total testosterone concentrations in the luteal phase. It seems that despite the stable resistin levels during the menstrual cycle, this adipokine plays at least an indirect role in the regulation of reproductive function. This hypothesis is partially supported by our previous observation obtained in PCOS women, which revealed an inverse association between serum LH concentrations and plasma resistin levels ([@bib31]). Our study provides a novel contribution by showing stable circulating levels of visfatin/NAMPT, omentin-1, apelin-36, RBP4 and IL-6 during the physiological menstrual cycle. Moreover, there were no associations between visfatin/NAMPT, omentin-1, apelin-36, RBP4 and IL-6 and gonadotropins levels during the menstrual cycle. Similarly, these adipokines were not associated with either estradiol or 17-OH progesterone concentrations in the follicular phase, with the exception of apelin-36, which was proportional to 17-OH progesterone levels. While in the midcycle, circulating omentin-1 and apelin-36 were proportional to 17-OH progesterone level, in the luteal phase, visfatin/NAMPT and apelin-36 levels were inversely associated with estradiol concentrations. A previous study demonstrated the stimulating effect of estrogen on visfatin/NAMPT secretion by adipocytes ([@bib32]). Interestingly, a different study was reported in which eutopic and ectopic endometrium apelin expression showed the cyclic changes ([@bib33]); however, it should be noted that in our study, circulating apelin levels were stable during the menstrual cycle. Although there is a lack of data concerning the effect of estrogens on visfatin/NAMPT production in women, the visfatin/NAMPT correlation with androstendione suggests a potential role of this adipokine in the regulation of adrenal gland function, which is difficult to explain. Furthermore, the exact role of visfatin/NAMPT on insulin resistance is doubtful.

One of the limitations of our study is the assessment of the parameters only three times in the cycle. A more robust study design would make assessments on every day of the menstrual cycle. Other limitations would be the lack of ultrasound monitoring of ovulation, and the indirect assessment of visceral fat deposits.

Conclusions
===========

Our results revealed stable levels of adipokines during the physiological menstrual cycle, except for leptin and vaspin levels, which increased in both the midcycle and the luteal phases. The changes in leptin and vaspin levels were found to be significantly associated with changes in the secretion of testosterone, 17-OH progesterone and insulin, in the luteal phase.

Declaration of interest
=======================

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
=======

Research was funded by grant from the Medical University of Silesia.
